Back to today’s briefing

Story perspectives

OpenAI Collaborates with FDA to Modernize Drug Approvals

5/8/2025

50 4

Summary

Story summary

OpenAI recently engaged with the U.S. FDA to explore the potential of cderGPT, an AI initiative aimed at speeding up drug evaluations. FDA Commissioner Marty Makary highlighted the urgent need to modernize approval processes. Despite the promise of increased efficiency, worries linger about AI's reliability and the necessity for clear policies on data usage.

1 of 1

Story summary

OpenAI recently engaged with the U.S. FDA to explore the potential of cderGPT, an AI initiative aimed at speeding up drug evaluations. FDA Commissioner Marty Makary highlighted the urgent need to modernize approval processes. Despite the promise of increased efficiency, worries linger about AI's reliability and the necessity for clear policies on data usage.